Drug shortage
Lisdexamfetamine Dimesylate Capsule · Takeda Pharmaceuticals USA Inc.
FDA drug shortage · Current · updated Apr 15, 2025
Key facts
| Generic name | Lisdexamfetamine Dimesylate Capsule |
|---|---|
| Proprietary name | Vyvanse |
| Company | Takeda Pharmaceuticals USA Inc. |
| Presentation | Vyvanse, Capsule, 60 mg (NDC 59417-106-10) |
| Dosage form | Capsule |
| Strength | 60 mg |
| Status | Current |
| Therapeutic category | Psychiatry |
| Package NDCs | 59417-106-10 |
| First posted | Jul 14, 2023 |
| Last updated | Apr 15, 2025 |
At a glance
- 1–9 Package NDCs affected
- 100–999 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: